ISSN:
1573-0646
Keywords:
Idarubicin
;
4-demethoxydaunorubicin
;
leukemia
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Idarubicin (IDR) is a new analog of Daunorubicin (DNR) selected for clinical trials because of its outstanding activity in experimental leukemias of mice and in several experimental models when compared to DNR and Doxorubicin. This Phase I trial was designed to determine the maximal tolerated dose in adult patients with acute leukemia refractory to prior treatment, using intravenously (I.V.) daily treatments for 5 consecutive days. Eleven patients were entered in this study. The initial dose of IDR was 4 mg/m2/d × 5 I.V. The highest dose given was 8 mg/m2/d × 5 I.V. Dose limiting toxicity were gastrointestinal side effects at the 8 mg/m2/d × 5 level (mucositis-diarrhea). Antileukemic activity has been detected in acute non-lymphoblastic leukemia not pretreated with anthracyclines. For Phase II adult leukemia studies using this schedule, it is recommended that the IDR dose should be 7 mg/m2/d.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00171588
Permalink
